These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22302442)

  • 21. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An improved method of evaluating drug effect in a multiple dose clinical trial.
    Shen L
    Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.
    Bruno R; Claret L
    Clin Pharmacol Ther; 2009 Aug; 86(2):136-8. PubMed ID: 19621009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A statistical model for the dependence between progression-free survival and overall survival.
    Fleischer F; Gaschler-Markefski B; Bluhmki E
    Stat Med; 2009 Sep; 28(21):2669-86. PubMed ID: 19579225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
    Denne JS; Stone AM; Bailey-Iacona R; Chen TT
    J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
    Heller G; Kattan MW; Scher HI
    Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating and adjusting for premature censoring of progression-free survival.
    Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
    J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.
    Shameer K; Zhang Y; Prokop A; Nampally S; N IKA; Weatherall J; Iacona RB; Khan FM
    JCO Clin Cancer Inform; 2022 Mar; 6():e2100173. PubMed ID: 35467964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
    J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-stage phase II trial design utilizing both primary and secondary endpoints.
    Lin X; Allred R; Andrews G
    Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of predictive probabilities in phase II and phase III clinical trials.
    Johns D; Andersen JS
    J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.